0PNT Acacia Pharma Group Plc

 
TIDMACPH 
 
   THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION. THIS ANNOUNCEMENT 
CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE 
REGULATION (EU) NO 596/2014 
 
   NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN 
WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, 
JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO 
DISTRIBUTE THIS ANNOUNCEMENT 
 
   Acacia Pharma Group plc 
 
   Results of Placing -- EUR 27 million Raised to Invest Further in US 
Launch and Commercialization Activities 
 
 
 
   Cambridge, UK and Indianapolis, US -- 19 February 2021, 08:00 CET: 
Acacia Pharma Group plc ("Acacia Pharma" or the "Company") (EURONEXT: 
ACPH), a commercial stage biopharmaceutical company focused on 
developing and commercializing novel products to improve the care of 
patients undergoing serious medical treatments such as surgery, invasive 
procedures, or chemotherapy, announces the successful completion of the 
placing announced yesterday (the "Placing"). 
 
   Capitalized terms not otherwise defined in this announcement have the 
meanings given to them in the announcement made by the Company at 13:15 
CET yesterday afternoon. 
 
   Pursuant to the Placing, Placees have agreed to subscribe for 10,000,000 
New Ordinary Shares at a price of EUR 2.70 per share (the "Placing 
Price"), which represents a 6.9 % discount to the last trading share 
price on 18 February 2021. The Placing will raise gross proceeds of 
approximately EUR 27,000,000. The New Ordinary Shares issued pursuant to 
the Placing represent 11.1% of the Company's issued share capital prior 
to the Placing. 
 
   Trading of Acacia Pharma shares was temporarily suspended as a result of 
the Bookbuild and shall resume today, as of the start of trading. 
 
   Bank Degroof Petercam SA/NV ("Degroof Petercam") is acting as Sole 
Bookrunner and Listing Agent (the "Sole Bookrunner" or the "Bank") in 
connection with the Placing. 
 
   Following issuance of the New Ordinary Shares, the total number of 
ordinary shares in issue in the Company will be 99,689,451. 
 
   Mike Bolinder, CEO of Acacia Pharma, commented: "We are very pleased 
with the rapid and successful completion of this Placing, which will 
provide us with the financial resources to support the continued launch 
and roll out of BARHEMSYS(R) and BYFAVO(TM) in the US. As we reported in 
yesterday's announcement, early progress in gaining formulary access for 
BARHEMSYS(R) has been very promising, exceeding our expectations, and 
comparing very favorably with recent comparable US hospital product 
launches. Gaining formulary acceptance is a crucial step to driving 
sales longer term, and we are delighted with the very positive early 
market reception to the US launch of BARHEMSYS(R) . We would like to 
thank our existing and new shareholders for their support and look 
forward to providing a further update on our progress at the time of our 
full year results in late March." 
 
   Acacia Pharma intends to use the net proceeds of the Placing: 
 
 
   1. To meet its sales force and marketing costs relating to BARHEMSYS(R) and 
      BYFAVO(TM) including brand development and engagement with key opinion 
      leaders, healthcare professionals and medical conference and speaker 
      programs; 
 
   2. To continue implementing post-approval research and development 
      commitments including pediatric studies for BARHEMSYS(R) and BYFAVO(TM) 
      and a renal study for BARHEMSYS(R); 
 
   3. To satisfy interest and principal payments under existing loan 
      agreements; and 
 
   4. For general corporate purposes relating to ongoing commercial activities. 
 
 
   In connection with the Placing, the Company has agreed to a lock-up 
undertaking, not to issue additional shares for a period of 90 days 
following settlement of the Placing. In addition, in connection with the 
Placing, senior managers and directors of the Company as well as Cosmo 
Technologies Limited ("Cosmo"), a substantial shareholder in the Company, 
have agreed not to sell any shares in Acacia Pharma for a period of 90 
days following the settlement of the Placing, subject to customary 
exceptions. 
 
   Application has been made to Euronext Brussels for admission of the New 
Ordinary Shares issued pursuant to the Placing to trading on the 
regulated market of Euronext Brussels ("Admission"). It is expected that 
Admission will take place on or around 08:00 CET on 23 February 2021 (or 
such later time or date as the Bank may agree with the Company) and that 
unconditional dealings in the New Ordinary Shares issued pursuant to the 
Placing will commence at the same time. The Placing is conditional upon, 
inter alia, Admission becoming effective and the placing agreement 
between the Company and the Bank not being terminated in accordance with 
its terms. 
 
   The payment and delivery of the New Ordinary Shares is expected to take 
place on 23 February 2021. 
 
   The New Ordinary Shares to be issued pursuant to the Placing will have 
the same rights and benefits as, and rank pari passu in all respects 
with, the Existing Ordinary Shares. 
 
   Contacts 
 
 
 
 
Acacia Pharma Group plc                          International Media 
 Mike Bolinder, CEO                               Mark Swallow, Frazer Hall, David 
 Gary Gemignani, CFO                              Dible 
 +44 1223 919760 / +1 317 505 1280                Citigate Dewe Rogerson 
 mailto:IR@acaciapharma.com IR@acaciapharma.com   +44 20 7638 9571 
                                                  mailto:acaciapharma@citigatedewerogerson.com 
                                                  acaciapharma@citigatedewerogerson.com 
-----------------------------------------------  --------------------------------------------- 
US Investors                                     Media in Belgium and the Netherlands 
 LifeSci Advisors                                 Chris Van Raemdonck 
 Irina Koffler                                    +32 499 58 55 31 
 +1 917-734-7387                                  mailto:chrisvanraemdonck@telenet.be 
 mailto:ikoffler@lifesciadvisors.com              chrisvanraemdonck@telenet.be 
 ikoffler@lifesciadvisors.com 
-----------------------------------------------  --------------------------------------------- 
 
   Acacia Pharma Group plc 
 
   The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United 
Kingdom 
 
   Company number 9759376 
 
   About Acacia Pharma 
 
   Acacia Pharma is a hospital pharmaceutical company focused on the 
development and commercialization of new products aimed at improving the 
care of patients undergoing significant treatments such as surgery, 
other invasive procedures, or cancer chemotherapy. The Company has 
identified important and commercially attractive unmet needs in these 
areas that its product portfolio aims to address. 
 
   Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is 
marketed in the US for the management of postoperative nausea & vomiting 
(PONV). 
 
   BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV 
benzodiazepine sedative is approved and launched in the US for use 
during invasive medical procedures in adults lasting 30 minutes or less, 
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion 
UK Limited for the US market. 
 
   APD403 (intravenous and oral amisulpride), a selective dopamine 
antagonist for chemotherapy induced nausea & vomiting (CINV) has 
successfully completed one proof-of-concept and one Phase 2 dose-ranging 
study in patients receiving highly emetogenic chemotherapy. 
 
   Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D 
operations are centered in Cambridge, UK. The Company is listed on the 
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker 
symbol ACPH. 
 
   https://www.globenewswire.com/Tracker?data=eTDqs6hQdZvG4dciFzvTTUw8PAK-DpDG83quGCa51NTs-P5UcWyibqUMllbiE04d8yREwwJZcwnnLzNVG2QGAP3xZpCXd8V_9fAeA9bVubw= 
www.acaciapharma.com 
 
   Important Information 
 
   These materials are not for release, publication or distribution, 
directly or indirectly, in whole or in part, into or within the United 
States (including its territories and possessions, any State of the 
United States and the District of Columbia). These materials are for 
informational purposes only and do not constitute or form part of any 
offer or solicitation to purchase or subscribe for securities in the 
United States. The securities referred to herein have not been and will 
not be registered under the United States Securities Act of 1933, as 
amended (the "US Securities Act"), or under the securities laws of any 
state or other jurisdiction of the United States. The securities 
referred to herein may not be offered or sold in the United States 
except pursuant to an exemption from the registration requirements of 
the US Securities Act and in compliance with any applicable securities 
laws of any state or other jurisdiction of the United States. There will 
be no public offer of securities in the United States. 
 
   This press release (and the information contained herein) is not for 
release, publication or distribution, directly or indirectly, in whole 
or in part, into or within Australia, Canada, Japan or South Africa or 
any other jurisdiction where to do so might constitute a violation of 
the relevant laws or regulations of such jurisdiction. 
 
   The offer set out in this press release is only addressed to and is only 
directed at persons in member states of the European Economic Area (the 
"EEA") who are "qualified investors" within the meaning of Article 2 (e) 
of Regulation (EU) 2017/1129. In the United Kingdom, this press release 
is addressed solely to, and is directed solely at, persons who (i) have 
professional experience in matters relating to investments falling 
within Article 19(5) of the Financial Services and Markets Act 2000 
(Financial Promotion) Order 2005 (the "Order") or (ii) are persons 
falling within Article 49(2)(a) to (e) of the Order and other persons to 

whom it may lawfully be communicated (all such persons together being 
referred to as "relevant persons"). These materials are addressed only 
to, and directed only at, relevant persons and qualified investors and 
must not be acted on or relied on (i) in the United Kingdom, by persons 
who are not relevant persons or (ii) in any member state of the EEA, by 
persons who are not qualified investors. Any investment or investment 
activity to which these materials relate is available only to, and any 
invitation, offer or agreement to subscribe, purchase or otherwise 
acquire any securities referred to herein will be engaged in only with, 
in the United Kingdom, relevant persons, and in any member state of the 
EEA, qualified investors. 
 
   This press release does not constitute, or form part of, any offer or 
any solicitation of an offer to subscribe for any shares or other 
securities. 
 
 
 
 

(END) Dow Jones Newswires

February 19, 2021 02:00 ET (07:00 GMT)

Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024

Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024